Saturday, 31 October 2026European Markets

PATRIMOINE ET COMM And BASSAC Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - patrimoine et comm (pat.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
patrimoine et comm (pat.pa) €18.50 7.54% 10.74%
bassac (bass.pa) €45.50 5.56% 14.33%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. patrimoine et comm (pat.pa)

7.54% forward dividend yield and 10.74% return on equity

patrimoine et commerce sa, a real estate company, engages in the acquisition, development, and operation of commercial real estate properties in france. the company operates a portfolio of 31 real estate assets covering a total area of 129,280 square meters located in high-attraction areas in the suburbs or centers of medium-sized cities. its property portfolio includes shopping malls, supermarkets, shops, and business parks. the company is based in boulogne-billancourt, france.

earnings per share

as for profitability, patrimoine et comm has a trailing twelve months eps of €3.05.

pe ratio

patrimoine et comm has a trailing twelve months price to earnings ratio of 6.07. meaning, the purchaser of the share is investing €6.07 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.74%.

more news about patrimoine et comm.

2. bassac (bass.pa)

5.56% forward dividend yield and 14.33% return on equity

bassac société anonyme operates as a real estate development company primarily in france, germany, and spain. it offers residential houses and apartments, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €9.59.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 4.74. meaning, the purchaser of the share is investing €4.74 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.33%.

volume

today's last reported volume for bassac is 180 which is 47.21% below its average volume of 341.

moving average

bassac's worth is under its 50-day moving average of €48.22 and under its 200-day moving average of €50.42.

yearly top and bottom value

bassac's stock is valued at €45.50 at 07:30 est, way under its 52-week high of €65.20 and higher than its 52-week low of €43.00.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, bassac's stock is considered to be oversold (<=20).

more news about bassac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com